Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.40 |
| ▸ | OGA | O60502 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 7/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | NCF1 | P14598 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19032186 | 0.85 | NPY2R (0.39) | OGAMEN1NCF1KMT2ACHRM4 | |
| SCHEMBL19032225 | 0.84 | MEN1 (0.46) | CYP2D6CYP1A2CYP2C19TSHRHIF1A | |
| SCHEMBL19032294 | 0.82 | NCF1 (0.44) | HSD17B10NCF1CHRM4ADRB2 | |
| SCHEMBL19032292 | 0.80 | CYP11B2 (0.44) | MEN1KMT2A | |
| SCHEMBL19032553 | 0.75 | MEN1 (0.45) | OGAMEN1KMT2A | |
| SCHEMBL19049710 | 0.75 | MEN1 (0.45) | OGAMEN1KMT2A | |
| SCHEMBL19049711 | 0.75 | MEN1 (0.45) | OGAMEN1KMT2A | |
| SCHEMBL25629403 | 0.71 | HTT (0.46) | CYP2D6CYP1A2CYP2C19TSHRHIF1A | |
| SCHEMBL25633236 | 0.69 | HTT (0.52) | CYP2D6CYP1A2CYP2C19TSHRHIF1A | |
| SCHEMBL25716737 | 0.69 | HTT (0.46) | CYP2D6CYP1A2CYP2C19TSHRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190010167-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. | 2019-01-10 | — | — | US | claimed |
| EP-3394064-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, Inc. (US) | 2018-10-31 | — | — | EP | claimed |
| WO-2017112768-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. (US) | 2017-06-29 | — | — | WO | claimed |
| US-20230095934-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH INHIBITORS OF MENIN | KURA ONCOLOGY, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20230026872-A1 | METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES AND EWING'S SARCOMA | KURA ONCOLOGY, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20190010167-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. | 2019-01-10 | — | — | US | disclosed |
| EP-3394064-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, Inc. (US) | 2018-10-31 | — | — | EP | disclosed |
| WO-2017112768-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017112768-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026872-A1 | METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES AND EWING'S SARCOMA | MEN1, DIAPH1, EWSR1 | CYP2D6 4625/4885OGA 3884/4885CYP1A2 4603/4885 |
| US-20230095934-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH INHIBITORS OF MENIN | MEN1, MCL1, XPOT | CYP2D6 4633/4885OGA 4151/4885CYP1A2 4686/4885 |
| US-20190010167-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | CYP2D6 4548/4885OGA 4636/4885CYP1A2 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.